- Consultant in Clinical Pharmacology at the National Hospital for Neurology and Neurosurgery (NHNN)
- Director of the NIHR Clinical Research Facility at UCLH
- Professor of Translational Neurology at UCL Institute of Neurology (ION)
- Director of the Masters in Translational Neuroscience at UCL
- Chair of the Health Research Authority-London Chelsea Research Ethics Committee
Prof Vincenzo Libri (MD, FRCP) obtained his MD degree and Specialist Training in Clinical Pharmacology in Italy in 1985 and 1989, respectively. Between 1990 and 1998, he was a Wellcome Trust and MRC Grant Holder at the Department of Pharmacology, The School of Pharmacy, London, UK. He was Lecturer in Pharmacology at the University of Rome, Italy, between 1994 and 1998. From 1998 to 2008, he undertook responsibility and leadership for translational medicine and early phase clinical trials across diseases in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly and GlaxoSmithKline).
From 2009 to 2013, he was Head of Clinical Studies at the NIHR Clinical Research Facility, Imperial College London, overseeing the running of the Centre and managing the whole portfolio of clinical studies. In October 2013 he was appointed founding Head of the Leonard Wolfson Experimental Medicine Centre (LWENC) at UCL-Institute of Neurology under a major capital award from the Wolfson Foundation. In April 2016 he took up the role of Director of the NIHR UCLH Clinical Research Facility integrating it with the LWENC in a single, integrated CRF at two sites, under a common leadership and teamwork. Since May 2020 he oversees the Covid-19 Vaccine programme at UCLH and leads the Covid-19 Vaccine Centre under the patronage of the UCLH Research Directorate.
Prof Libri has long lasting expertise in clinical pharmacology, translational neurology and early phase clinical trials across diseases. His main research interests include Motor Neurone Disease, Alzheimer's disease, Friedreich's ataxia, and SARS-COV-2 vaccine trials. He has published several peer reviewed original research papers in international medical journals including the Lancet and the New England Journal of Medicine. He is Principal Investigator/Co-investigator of several early phase clinical trials in neurodegenerative diseases targeting innovative therapeutic targets, including antisense oligonucleotides for motor neurone disease. He is also PI/co-I of a series of designated Urgent Public Health Covid-19 vaccine trials at UCLH, including the Oxford/AstraZeneca COV002 pivotal trial leading to marketing authorization; the AstraZeneca/Pfizer combination trials COM-COV1 and COM-COV2; the booster vaccination trial COV-BOOST; the Imperial COVAC1 phase I trial; the Valneva vaccine phase II/III trial; the Pfizer vaccine trial in pregnant women; the AstraZeneca monoclonal antibody trials STORM-CHASER and PROVENT for COVID-19 prophylaxis.
Prof Libri has several years of teaching experience to both undergraduate and MBBS and BSc students and is the founding Director of the MRes in Translational Neuroscience within the Faculty of Brain Sciences at UCL. He is also visiting Professor in Clinical Pharmacology at the University of Naples, Italy.
Prof Libri is a member of several internal and external research committees and boards, including the UCLH/UCL BRC Executive Board; the UCL Institute for Precision Medicine Steering Committee, the CTIMP Sponsorship Committee at GOSH, among others. He is external referee/assessor of several funding schemes for research, fellowships and infrastructure awards, including the ARUK Global Clinical Trials Fund for early phase clinical trials in Dementia; the ICM (Institut du Cerveau et de la Moelle épinière, Paris, Fr)-ICRIN (Clinical Research Infrastructures in Neurosciences) Award; the MIUR (Italian Ministry of Education, University and Research)-PRIN (Research Projects of National Interest) Referee Evaluation Panel, and other committees.
E-mail: vincenzo.libri@ucl.ac.uk
